1. Signaling Pathways
  2. Immunology/Inflammation
  3. IRAK
  4. IRAK4 Isoform
  5. IRAK4 Inhibitor

IRAK4 Inhibitor

IRAK4 Inhibitors (32):

Cat. No. Product Name Effect Purity
  • HY-19836
    Zimlovisertib
    Inhibitor 99.84%
    Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively.
  • HY-135317
    Emavusertib
    Inhibitor 99.96%
    Emavusertib (CA-4948) is a potent IRAK4/FLT3 inhibtor with anti-tumor activity.
  • HY-129966
    PROTAC IRAK4 degrader-1
    Inhibitor 99.72%
    PROTAC IRAK4 degrader-1 is a Cereblon-based PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1 Compound I-210, makes <20%, >20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively.
  • HY-111101
    AZ1495
    Inhibitor 98.18%
    AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor.
  • HY-147141
    HS-276
    Inhibitor 98.59%
    HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a Ki of 2.5 nM.
  • HY-134911
    HS-243
    Inhibitor 99.88%
    HS-243 is a potent and selective IRAK-4 and IRAK-1 inhibitor, with IC50 values of 20 and 24 nM.
  • HY-145483
    PROTAC IRAK4 degrader-7
    Inhibitor
    PROTAC IRAK4 degrader-7 (Compound I-417) is an orally active PROTAC IRAK4 degrader with antitumor activities.
  • HY-150732
    IRAK4-IN-18
    Inhibitor
    IRAK4-IN-18 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 value of 15 nM.
  • HY-109585
    IRAK4-IN-7
    Inhibitor 99.86%
    IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1).
  • HY-123854
    PF-06426779
    Inhibitor 99.83%
    PF-06426779 is a potent and selective inhibitor of interleukin‑1 receptor associated kinase 4 (IRAK4), with an IC50 of 0.3 nM.
  • HY-77048
    IRAK-4 protein kinase inhibitor 2
    Inhibitor 99.48%
    IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM.
  • HY-131903
    HS271
    Inhibitor 99.92%
    HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC50 of 7.2 μM.
  • HY-18992
    AS2444697
    Inhibitor 98.13%
    AS2444697 is an orally active IRAK-4 inhibitor with an IC50 of 21 nM.
  • HY-135382A
    PROTAC IRAK4 degrader-3
    Inhibitor
    PROTAC IRAK4 degrader-3 is a PROTAC-induced IRAK4 degrader based on von Hippel-Lindau.
  • HY-143231
    IRAK4-IN-8
    Inhibitor
    IRAK4-IN-8 (VI-177) is a potent IRAK4 inhibitor.
  • HY-139316
    PROTAC IRAK4 degrader-5
    Inhibitor
    PROTAC IRAK4 degrader-5 is a Cereblon-based IRAK4 degrader extracted from patent US20190192668A1, compound I-171.
  • HY-150593
    IRAK4-IN-16
    Inhibitor
    IRAK4-IN-16 (compound 4) is a potent IRAK4 (interleukin-1 receptor associated kinase 4) inhibitor, with an IC50 of 2.5 nM.
  • HY-143485
    IRAK4-IN-9
    Inhibitor
    IRAK4-IN-9 (compound 73) is a potent IRAK4 inhibitor with an IC50 of 1.5 nM.
  • HY-143486
    IRAK4-IN-10
    Inhibitor
    IRAK4-IN-10 (compound 75) is a potent IRAK4 inhibitor with an IC50 of 1.5 nM.
  • HY-146111
    IRAK4-IN-13
    Inhibitor
    IRAK4-IN-13 (compound 21) is a potent and selective IRAK4 inhibitor with an IC50 of 0.6 nM.